Summary
Although the beneficial effect on breast cancer of adjuvant tamoxifen (TAM) is well established, in the series studied by our group this effect seems to have been restricted to patients with steroid receptor (especially progesterone receptor (PgR)) positive tumors. However, as some patients with PgR-positive tumors manifested recurrence despite adjuvant TAM treatment, the question arose whether some other biological factor(s) could be used to identify these non-responding cases. The level of the S-phase fraction (SPF), as measured by flow cytometry, has been shown to be a useful prognostic marker, prognosis being better in cases where the SPF is low than in those where it is high. The aim of the present study was to relate the prognosis after adjuvant TAM to SPF among patients with PgR-positive tumors.
In the PgR-positive group as a whole, the effect of TAM on prognosis was more pronounced in the high SPF group than in the low SPF group (p = 0.005) the respective decrease in 3 year recurrence rate was from 19 to 43% and from 17 to 9%. Multivariate analysis of the data for the TAM-treated group showed the level of PgR concentration (low positivevs. high positive), lymph node status, and tumor size to be independent predictive factors, but not the level of SPF (i.e. highvs. low). By contrast, among patients not treated with TAM, the SPF was a strong independent prognostic factor.
To sum up, SPF was a strong independent predictor of outcome only for patients receiving no systemic adjuvant therapy, but not in patients receiving adjuvant TAM. Patients with PgR-positive and high S-phase tumors derived more benefit from TAM than patients with PgR-positive and low SPF tumors.
Article PDF
Avoid common mistakes on your manuscript.
References
Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1–15, 71-85, 1992
Rutqvist LE, Cedermark B, Glas U, Johansson H, Nordenskjöld B, Skoog L, Somell A, Theve T, Friberg S, Askergren J: The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 10: 255–266, 1987
Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M, Rasmussen BB: Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet i: 16–19, 1985
Rydén S, Fernö M, Borg Å, Hafström Lo, Möller T, Norgren A: Prognostic significance of estrogen and progesterone receptors in stage II breast cancer. J Surg Oncol 37: 221–226, 1988
Baum M: Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Analysis at eight years by Nolvadex Adjuvant Trial Organisation. Br J Cancer 57: 608–611, 1988
Rydén S, Fernö M, Borg Å, Möller T: Progesterone receptors predict response to adjuvant tamoxifen in premenopausal patients. Fourth Int Meeting Adjuvant Ther Breast Cancer, St Gallen 1992
McGuire WL: An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. In: Iacobelli Set al. (eds) Hormones and Cancer. Raven Press, New York, 1980, pp 337–343
Stewart HJ: Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC) Edingburgh. Lancet ii, 171–175, 1987
Nicholson RI, Campbell FC, Davies P: The endocrinology of antiestrogen action on breast cancer. Rev Endocrine-Related Cancer (suppl.) 13: 39–43, 1983
Ravdin PM, Gren S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, Metch B, Osborne CK: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group Study. J Clin Oncol 10 (8): 1284–1291, 1992
Nicholson RI, Bouzubar N, Walker KJ, McClelland R, Dixon AR, Robertson JFR, Ellis IO, Blamey RW: Hormone sensitivity in breast cancer: Influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur J Cancer 27 (7): 908–913, 1991
Borg Å, Baldetorp B, Fernö M, Killander D, Olsson H, Rydén S, Sigurdsson H: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Letters 81: 137–144, 1994
Predine J, Spyratos F, Prud'homme JF, Andrieu C, Hacene K, Brunet M, Pallud C, Milgrom E: Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Cancer 69: 2116–2123, 1992
Knabbe E, Lippman ME, Wakefield LM: Evidence that transforming growth factor-Beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417–428, 1987
Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627–633, 1989
Sigurdsson H, Baldetorp B, Borg Å, Dalberg M, Fernö M, Killander D, Olsson H: Indicators of prognosis in node-negative breast cancer. N Engl J Med 322: 1045–1053, 1990
Kallioniemi O-P, Hietanen T, Mattila J, Lehtinen M, Lauslahti K, Koivula T: Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. Eur J Cancer Clin Oncol 23: 277–282, 1987
Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D: Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 14: 482–485, 1993
Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Magdelénat H, Pouillart P: Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 81: 1383–1387, 1989
O'Reilly SM, Camplejohn RS, Rubens RD, Richards MA: DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer 28: 681–683, 1992
Fernö M, Borg Å, Norgren A: A comparison of two steroid receptor assays in breast cancer: dextran coated charcoal and isoelectric focusing. Anticancer Res 3: 243–246, 1983
Fernö M, Borg Å, Sellberg G: Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing. Acta Radiol Oncol 25: 171–175, 1986
Fernö M, Borg Å, Johansson U: Enzyme immuno assay of progesterone receptor in breast cancer biopsy samples: A comparison with the dextran coated charcoal method. Acta Oncol 28: 19–22, 1989
Fernö M, Borg Å, Johansson U, Norgren A, Olsson H, Rydén S, Sellberg G, Southern Swedish Breast Cancer Study Group: Estrogen and progesterone receptor analysis in more than 4000 human breast cancer samples. A study with special reference to age at diagnosis and stability of analyses. Acta Oncol 29: 129–135, 1990
Thornthwaite JT, Sugerbaker EV, Temple WJ: Preparation of tissue for DNA flow cytometric analysis. Cytometry 1: 229–237, 1980
Lee GM, Thornthwaite JT, Rasch EM: Picogram per cell determination of DNA by flow cytofluorometry. Analyt Biochem 137: 221–226, 1984
Baldetorp B, Dalberg M, Holst U, Lindgren G: Statistical evaluation of cell kinetic data from DNA flow cytometry (FCM) by the EM algorithm. Cytometry 10: 695–705, 1989
Vindelöv LL, Christensen IB, Nissen NI: Standardization of high resolution flow cytometric DNA analysis by the simultaneous use of chicken and trout red blood cells as internal reference standards. Cytometry 3: 328–331, 1983
Hiddeman W, Schumann J, Andreeff M, Barlogie B, Herman CJ, Leif RC, Mayall BH, Murphy RF, Sandberg AA: Convention on nomenclature for DNA cytometry. Cytometry 5: 445–446, 1984
Baisch H, Gohde W, Linden WA: Analysis of PCP-data to determine the fraction of cells in various phases of cell cycle. Radiat Environ Biophys 12: 31–39, 1975
Sigurdsson H, Baldetorp B, Borg Å, Dalberg M, Fernö M, Killander D, Olsson H, Ranstam J: Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels. Br J Cancer 62: 786–790, 1990
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958
Savage IR: Contribution to the theory of rank order statistics- two sample case. Annals of Mathematical Statistics 27: 590–615, 1956
Altman DG: Practical Statistics for Medical Research, pp 386. Chapman & Hall, London, 1991
Cox DR: Regression models and life-tables. J R Stat Soc (B) 34: 187–220, 1972
Schoenfeld D: Chi-squared goodness-of-fit tests for the proportional hazards regression model. Biometrika 67:145–153, 1980
Jordan VC, Murphy CS: Endocrine pharmacology of antiestrogens as antitumor agents. Endocrine Rev 11 (4): 578–610, 1990
Sutherland RL, Watts CK, Hall RE, Ruenitz PC: Mechanisms of growth inhibition by nonsteroidal antiestrogens in human breast cancer cells. J Steroid Biochem 27 (4-6): 891–897, 1987
Vicard E, Hijazi A, Muchada E, Chouvet C, Devonec M, Saez S: Flow cytometry analysis of the growth inhibitory effect of 4-hydroxy-tamoxifen on a human breast carcinoma cell line. Anticancer Res 8: 375–380, 1988
Clark RB, Laidlaw IJ, Jones LJ, Howell A, Anderson E: Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 67: 606–611, 1993
Nordenskjöld B, Löwhagen T, Westerberg H, Zajicek J:3H-thymidine incorporation into mammary carcinoma cells obtained by needle aspiration before and during endocrine therapy. Acta Cytol 20: 137–143, 1976
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fernö, M., Baldetorp, B., Bendahl, PO. et al. Recurrence-free survival in breast cancer improved by adjuvant tamoxifen -especially for progesterone receptor positive tumors with a high proliferation. Breast Cancer Res Tr 36, 23–34 (1995). https://doi.org/10.1007/BF00690181
Issue Date:
DOI: https://doi.org/10.1007/BF00690181